FAKTOR OPTIONSSCHEIN - ROCHE GS Stock

Certificat

DE000GB1Y0M5

Market Closed - BOERSE MUENCHEN 14:25:55 2024-06-26 EDT
0.482 EUR -8.71% Intraday chart for FAKTOR OPTIONSSCHEIN - ROCHE GS
Current month+46.06%
1 month+48.31%
Date Price Change
24-06-26 0.482 -8.71%
24-06-25 0.528 -0.94%
24-06-24 0.533 +3.09%
24-06-21 0.517 +5.73%
24-06-20 0.489 +0.62%

Real-time BOERSE MUENCHEN

Last update June 26, 2024 at 02:25 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GB1Y0M
ISINDE000GB1Y0M5
Date issued 2019-09-05
Strike 202.7 CHF
Maturity Unlimited
Parity 103.02 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 12.8
Lowest since issue 0.237
Spread 0.01
Spread %2.08%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.40%
Consensus